GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Yazar
Tural, Deniz
Gautschi, Oliver
Zirtiloglu, Alisan
Eralp, Yesim
Cinkir, Havva Yesil
Sezer, Ahmet
ERMAN, MUSTAFA
Turna, Hande
Yumuk, Perran Fulden
Yildiz, Ibrahim
Kaplan, M. Ali
ÖZYILKAN, ÖZGÜR
Oztop, Ilhan
Olmez, Omer Fatih
Aydin, Kubra
Aydiner, Adnan
Meydan, Nezih
Grinberg, Roxana Denisa
Roisman, Laila C.
ÇABUK, DEVRİM
Isikdogan, Abdurrahman
Sendur, Mehmet Ali Nahit
Coskun, Hasan Senol
Okutur, Kerem
Karaoglu, Aziz
Demirkazik, Ahmet
Yazilitas, Dogan
Beypinar, Ismail
Senler, Filiz Cay
Ng, Terry L.
Camidge, David Ross
Dudnik, Elizabeth
Reguart, Noemi
Mazieres, Julien
Peled, Nir
Gillis, Roni
KILIÇKAP, SAADETTİN
Froesch, Patrizia
Orlov, Sergei
Filippova, Elena
Demirci, Umut
Christopoulos, Petros
ÇİÇİN, İRFAN
Basal, Fatma Bugdayci
Yilmaz, Cengiz
Fedor, Moiseenko
Korkmaz, Taner
Paydas, Semra
Üst veri
Tüm öğe kaydını göster
Özet
Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.
Bağlantı
http://hdl.handle.net/20.500.12627/19120
https://doi.org/10.1016/j.lungcan.2020.07.022
Koleksiyonlar